Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that while MK-0773 significantly increased lean body mass in sarcopenic frail elderly women, it did not significantly improve muscle strength or physical function compared to placebo.

This study found that selective androgen receptor modulators (SARMs) significantly inhibited tumor growth and metastasis-promoting factors in AR-positive triple-negative breast cancer models.

This study by Gao et al. reports that two nonsteroidal selective androgen receptor modulators, S1 and S4, demonstrated tissue-selective actions in rats, suppressing prostate growth while maintaining muscle growth without altering hormone levels.

This study found that GTx-024 and Danazol had similar effects to dihydrotestosterone on uterine tissue in mice, while GTx-007 showed minimal impact on the parameters tested.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

This study found evidence of structurally and functionally distinct AR-SARM protein complexes, which may contribute to understanding how SARMs achieve tissue-selective effects.

This article reviews the potential clinical use of anabolic steroids in treating muscle loss from chronic diseases and aging and highlights both the benefits and risks of these substances in sports.

This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.

This study synthesized nonsteroidal ligands as second-generation androgen receptor agonists and identified three compounds with significant anabolic activity and moderate to minimal androgenic activity in vivo.

New treatments for male hypogonadism are effective and should be personalized.

This review discusses nonsteroidal selective androgen receptor modulators and their potential therapeutic applications but reports no new clinical findings.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

This review discusses the role of skeletal muscle in synthesizing bioactive androgens, highlighting that intramuscular androgens may influence muscle via intracrine action, but their precise function remains unclear.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This review examines the benefits and potential risks of androgen replacement therapy for male hypogonadism but reports no new clinical results; the authors highlight the need for careful risk assessment, especially in older men.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.

This review discusses current challenges in selective androgen receptor modulator discovery and preclinical evaluation and reports no new results, emphasizing the need for basic research to improve safety and selectivity.

This review discusses trends in testosterone therapy use for male hypogonadism and reports no new clinical results, noting a shift towards more convenient and physiological treatments.

This chapter reviews the biosynthesis, mechanism of action, and therapeutic effects of testosterone and related androgens, but reports no new research findings.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

This article reviews the development of selective androgen receptor modulators and myostatin inhibitors as performance-enhancing drugs, highlighting ongoing challenges in achieving truly tissue-selective anabolic agents and reporting no new experimental findings.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.